BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome (BAFF/IL-17)
Primary Purpose
Primary Sjogren's Syndrome
Status
Withdrawn
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
tibulizumab (LY3090106)
Sponsored by

About this trial
This is an interventional treatment trial for Primary Sjogren's Syndrome
Eligibility Criteria
Inclusion Criteria:
- Men and women 18-85 years of age
- Confirmed diagnosis of primary Sjogren's syndrome by the 2016 ACR-EULAR classification criteria for primary Sjogren's syndrome
- All women (regardless of childbearing potential) must test negative for pregnancy at the time of screening
- Women must also agree to use a reliable method of birth control from screening until 12 weeks following last dose of study drug unless they are not of child bearing potential
- Have stimulated whole salivary flow rate of greater than or equal to 0.10 ml/minute
- Have a salivary gland total ultrasound score (TUS) of less than or equal to 9 (on a 0-11 point scale)
Exclusion Criteria:
- Currently enrolled in a clinical trial involving an investigational product or off-label use of a drug
- Concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
- Have received any nonbiologic investigational product within 30 days or 5 half-lives (whichever is longer) of their baseline (Day 1) visit
- Have received any biologic investigational product within 3 months or 5 half-lives (whichever is longer) of their baseline visit, or any leukocyte depleting agent within 12 months of baseline
Have disease-modifying antirheumatic drug (DMARD) or immunosuppressive use as follows:
- ANY treatment with a janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, upadacitinib, or filgotinib) within 28 days prior to baseline or planned treatment with a JAK inhibitor during the study
- UNSTABLE PRESCRIBED DOSE of other synthetic DMARDs (eg, hydroxychloroquine, methotrexate, leflunomide, or sulfasalazine) within 28 days prior to baseline or if the dose of drug is planned to be increased during the study (stable prescriptions are allowed)
- ANY treatment with cytotoxic or immunosuppressive drugs including but not limited to cyclophosphamide, mycophenolic acid, azathioprine, cyclosporine, sirolimus, or tacrolimus within 28 days prior to screening or planned treatment during the study
- Have had treatment with biologic DMARDs as follows: Etanercept, adalimumab, or anakinra <4 weeks before baseline or planned treatment during the study
- Have had treatment with biologic DMARDs as follows: Infliximab, certolizumab pegol, golimumab, abatacept, or tocilizumab <8 weeks before baseline or planned treatment during the study
- Are persons who have previously completed or withdrawn from this study
Sites / Locations
- Stanford University
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
open label
Arm Description
open label study; all subjects will receive the same drug at the same dose
Outcomes
Primary Outcome Measures
whole unstimulated sialometry
change in unstimulated salivary flow
whole unstimulated sialometry
change in unstimulated salivary flow
salivary gland ultrasound
change in salivary gland ultrasound score
salivary gland ultrasound
change in salivary gland ultrasound score
Secondary Outcome Measures
ESSDAI
change in the ESSDAI disease activity score
The EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is a physician administered questionnaire containing 12 organ-specific domains designed to measure disease activity. The ESSDAI score is obtained by addition of the twelve domain scores. Each domain score is obtained by multiplying the activity level with the domain weight. The maximum theoretical ESSDAI score is 123 and the minimum score is 0. A higher score means more disease activity (worse outcome).
ESSDAI
change in the ESSDAI disease activity score
The EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is a physician administered questionnaire containing 12 organ-specific domains designed to measure disease activity. The ESSDAI score is obtained by addition of the twelve domain scores. Each domain score is obtained by multiplying the activity level with the domain weight. The maximum theoretical ESSDAI score is 123 and the minimum score is 0. A higher score means more disease activity (worse outcome).
ESSPRI
change in the ESSPRI disease activity score
The EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) is a patient completed questionnaire to assess subjective patient symptoms, which includes 3 domains (dryness, fatigue, and pain). The ESSPRI score is calculated by averaging the three domains with a maximum severity score of 10 and minimum score of 0. A higher score means more disease activity (worse outcome).
ESSPRI
change in the ESSPRI disease activity score
The EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) is a patient completed questionnaire to assess subjective patient symptoms, which includes 3 domains (dryness, fatigue, and pain). The ESSPRI score is calculated by averaging the three domains with a maximum severity score of 10 and minimum score of 0. A higher score means more disease activity (worse outcome).
whole stimulated sialometry
change in stimulated salivary flow rate
whole stimulated sialometry
change in stimulated salivary flow rate
Schirmer I test
change in the Schirmer I test
Schirmer I test
change in the Schirmer I test
MRI
change in MRI (parenchymal architecture scored 0 to 4 and sialography scored 0 to 4)
MRI
change in MRI (parenchymal architecture scored 0 to 4 and sialography scored 0 to 4)
PET
change in PET (parotid and submandibular gland SUVmax)
PET
change in PET (parotid and submandibular gland SUVmax)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04563195
Brief Title
BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome
Acronym
BAFF/IL-17
Official Title
BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
January 2022
Overall Recruitment Status
Withdrawn
Why Stopped
Drug unavailable
Study Start Date
February 1, 2022 (Anticipated)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
January 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Matthew C. Baker
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To demonstrate that tibulizumab (LY3090106) treatment improves the mean unstimulated salivary flow rate or the salivary gland total ultrasound score (TUS) in primary Sjogren's syndrome patients at week 12 compared to the baseline visit.
Detailed Description
This will be a single-site, open-label study in patients with primary Sjogren's syndrome. All patients will receive tibulizumab (LY3090106) 300mg subcutaneously every 2 weeks for a total of 12 weeks.
Primary Sjogren's syndrome was selected as a relevant patient population based on the mechanism of action of the molecule and the current understanding of the pathogenesis of the disease. An open-label design was chosen based on practical considerations regarding the number of patients that could be recruited. Although open-label studies are subject to bias, objective primary endpoints were intentionally chosen to minimize this concern.
The goal of this study is to demonstrate that tibulizumab (LY3090106) treatment improves the mean unstimulated salivary flow rate or the salivary gland total ultrasound score (TUS) in primary Sjogren's syndrome patients at week 12 compared to the baseline visit.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Sjogren's Syndrome
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
open label
Arm Type
Other
Arm Description
open label study; all subjects will receive the same drug at the same dose
Intervention Type
Drug
Intervention Name(s)
tibulizumab (LY3090106)
Other Intervention Name(s)
open label
Intervention Description
subcutaneous injections of 300mg every 2 weeks over a period of 12 weeks
Primary Outcome Measure Information:
Title
whole unstimulated sialometry
Description
change in unstimulated salivary flow
Time Frame
baseline
Title
whole unstimulated sialometry
Description
change in unstimulated salivary flow
Time Frame
week 12
Title
salivary gland ultrasound
Description
change in salivary gland ultrasound score
Time Frame
baseline
Title
salivary gland ultrasound
Description
change in salivary gland ultrasound score
Time Frame
week 12
Secondary Outcome Measure Information:
Title
ESSDAI
Description
change in the ESSDAI disease activity score
The EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is a physician administered questionnaire containing 12 organ-specific domains designed to measure disease activity. The ESSDAI score is obtained by addition of the twelve domain scores. Each domain score is obtained by multiplying the activity level with the domain weight. The maximum theoretical ESSDAI score is 123 and the minimum score is 0. A higher score means more disease activity (worse outcome).
Time Frame
baseline
Title
ESSDAI
Description
change in the ESSDAI disease activity score
The EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is a physician administered questionnaire containing 12 organ-specific domains designed to measure disease activity. The ESSDAI score is obtained by addition of the twelve domain scores. Each domain score is obtained by multiplying the activity level with the domain weight. The maximum theoretical ESSDAI score is 123 and the minimum score is 0. A higher score means more disease activity (worse outcome).
Time Frame
week 12
Title
ESSPRI
Description
change in the ESSPRI disease activity score
The EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) is a patient completed questionnaire to assess subjective patient symptoms, which includes 3 domains (dryness, fatigue, and pain). The ESSPRI score is calculated by averaging the three domains with a maximum severity score of 10 and minimum score of 0. A higher score means more disease activity (worse outcome).
Time Frame
baseline
Title
ESSPRI
Description
change in the ESSPRI disease activity score
The EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) is a patient completed questionnaire to assess subjective patient symptoms, which includes 3 domains (dryness, fatigue, and pain). The ESSPRI score is calculated by averaging the three domains with a maximum severity score of 10 and minimum score of 0. A higher score means more disease activity (worse outcome).
Time Frame
week 12
Title
whole stimulated sialometry
Description
change in stimulated salivary flow rate
Time Frame
baseline
Title
whole stimulated sialometry
Description
change in stimulated salivary flow rate
Time Frame
week 12
Title
Schirmer I test
Description
change in the Schirmer I test
Time Frame
baseline
Title
Schirmer I test
Description
change in the Schirmer I test
Time Frame
week 12
Title
MRI
Description
change in MRI (parenchymal architecture scored 0 to 4 and sialography scored 0 to 4)
Time Frame
baseline
Title
MRI
Description
change in MRI (parenchymal architecture scored 0 to 4 and sialography scored 0 to 4)
Time Frame
week 12
Title
PET
Description
change in PET (parotid and submandibular gland SUVmax)
Time Frame
baseline
Title
PET
Description
change in PET (parotid and submandibular gland SUVmax)
Time Frame
week 12
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Men and women 18-85 years of age
Confirmed diagnosis of primary Sjogren's syndrome by the 2016 ACR-EULAR classification criteria for primary Sjogren's syndrome
All women (regardless of childbearing potential) must test negative for pregnancy at the time of screening
Women must also agree to use a reliable method of birth control from screening until 12 weeks following last dose of study drug unless they are not of child bearing potential
Have stimulated whole salivary flow rate of greater than or equal to 0.10 ml/minute
Have a salivary gland total ultrasound score (TUS) of less than or equal to 9 (on a 0-11 point scale)
Exclusion Criteria:
Currently enrolled in a clinical trial involving an investigational product or off-label use of a drug
Concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
Have received any nonbiologic investigational product within 30 days or 5 half-lives (whichever is longer) of their baseline (Day 1) visit
Have received any biologic investigational product within 3 months or 5 half-lives (whichever is longer) of their baseline visit, or any leukocyte depleting agent within 12 months of baseline
Have disease-modifying antirheumatic drug (DMARD) or immunosuppressive use as follows:
ANY treatment with a janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, upadacitinib, or filgotinib) within 28 days prior to baseline or planned treatment with a JAK inhibitor during the study
UNSTABLE PRESCRIBED DOSE of other synthetic DMARDs (eg, hydroxychloroquine, methotrexate, leflunomide, or sulfasalazine) within 28 days prior to baseline or if the dose of drug is planned to be increased during the study (stable prescriptions are allowed)
ANY treatment with cytotoxic or immunosuppressive drugs including but not limited to cyclophosphamide, mycophenolic acid, azathioprine, cyclosporine, sirolimus, or tacrolimus within 28 days prior to screening or planned treatment during the study
Have had treatment with biologic DMARDs as follows: Etanercept, adalimumab, or anakinra <4 weeks before baseline or planned treatment during the study
Have had treatment with biologic DMARDs as follows: Infliximab, certolizumab pegol, golimumab, abatacept, or tocilizumab <8 weeks before baseline or planned treatment during the study
Are persons who have previously completed or withdrawn from this study
Facility Information:
Facility Name
Stanford University
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome
We'll reach out to this number within 24 hrs